# Clinical Policy: Ferriscan R2-MRI

Reference Number: PA.CP.MP.53

Effective Date: 10/18

**Description**

FerriScan R2-MRI is a magnetic resonance imaging (MRI) -based solution for measuring liver iron concentration (LIC) in patients with iron overload.

**Policy/Criteria**

**I.** It is the policy of Pennsylvania Health and Wellness® (PHW), that the FerriScan® R2-MRI is **medically necessary** for the measurement of liver iron concentration in suspected cases of iron overload due to the following conditions:

**A.** Hereditary hemochromatosis;

**B.** Iron-loading anemias with or without multiple transfusions:
1. Thalassemia major and thalassemia intermedia;
2. Sideroblastic anemia;
3. Chronic hemolytic anemias (e.g., sickle cell disease);
4. Inherited or acquired aplastic anemia;
5. Myelodysplastic syndromes;

**C.** Dietary iron overload;

**D.** Iron overload in liver diseases:
1. Hepatitis C and B;
2. Alcohol-induced liver disease;
3. Porphyria cutanea tarda;
4. Fatty liver disease;
5. Gestational alloimmune liver disease

**E.** Neonatal iron overload;

**F.** Aceruloplasminemia;

**G.** Repeated hemin infusions for acute porphyrias.

**Background**

FerriScan® is a non-invasive technology based on MRI. It has a high sensitivity and specificity for the measurement of LIC over the entire range encountered in clinical practice. It can be set up on most 1.5 Tesla MRI scanners (the most common type of clinical scanner). FerriScan makes a map of the liver iron concentration and calculates the mean LIC. The results are unaffected by the presence of fibrosis or cirrhosis. Image data is acquired on an MRI scanner and is electronically transmitted to a data analysis center. All data is analyzed to ensure correct acquisition and the LIC results are transmitted back to the originating MRI center.

The operational principle of the R2-MRI Analysis System is based on fitting signal decay curves to the image signal intensities (e.g. of the liver) at the different echo times for the MR data set on a voxel-by-voxel (3-D pixel) basis to determine transverse relaxation rate (R2) images. These may be further transformed by a defined calibration to provide a quantitative measure of liver iron concentrations.

Measurements have been shown to have a high degree of sensitivity and specificity for liver iron concentration measured by biopsy. FerriScan images give information on liver iron distribution. The mean LIC value given in the FerriScan report is then used to guide chelation therapy.

Magnetic resonance evaluation for hepatic iron concentration is improved compared with programs that were used several years ago. However, this type of imaging will not detect cellular liver damage due to iron overload.

The American College of Radiology's 2015 Practice Parameter for the performance of MRI of the liver states that indications for MRI of the liver include hemochromatosis, hemosiderosis, or steatosis. Additionally, multiple studies have confirmed the clinical utility of R2 MRI in the measurement of LIC for iron-overloading conditions such as thalassemia[7] and sickle cell anemia[8]. A study of R2 MRI results vs. simulated liver biopsy results found R2 MRI to be superior to liver biopsy for serial LIC observations[9]. Furthermore, a review of the current state of liver iron quantification by MRI states that R2 MRI provides validated measurement of LIC, and has advantages over liver biopsy, in that is in non-invasive.[10]

The R2-MRI Analysis System (Inner Vision Biometrics PTY LTD) received FDA 510(k) clearance (K043271) on January 21, 2005. In January 2013, the FDA authorized the FerriScan R2-MRI to be marketed as an imaging companion diagnostic device for the safe and effective use of Exjade in patients with non-transfusion-dependent thalassemia.

**Coding Implications**
This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2018, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| CPT®* Codes | Description |
| --- | --- |
| 76498 | Unlisted MRI procedure |

**ICD-10-CM Diagnosis Codes that Support Coverage Criteria**

| ICD-10-CM Code | Description |
| --- | --- |
| B16.0-B1.9 | Acute hepatitis B |
| B17.10-B17.11 | Acute hepatitis C |
| B18.0 | Chronic viral hepatitis B, with delta -agent |
| B18.1 | Chronic viral hepatitis B without delta-agent |
| B18.2 | Chronic viral hepatitis C |
| B19.10-B19.11 | Unspecified viral hepatitis B |
| B19.20-B19.21 | Unspecified viral hepatitis C |

| ICD-10-CM Code | Description |
|---|---|
| D46.0 | Refractory anemia without ring sideroblasts, so stated |
| D46.1 | Refractory anemia with  ring sideroblasts |
| D46.20-D46.22 | Refractory anemia with excess of blasts |
| D56.1 | Beta thalasemia |
| D61.01- D61.8 | Constititional aplastic anemia |
| D61.89 | Other specified aplastic anemias and other bone marrow failure syndromes |
| D61.9 | Aplastic anemia, unspecified |
| D64.0 | Hereditary sideroblastic anemia |
| D64.1 | Secondary sideroblastic anemia due to disease |
| D64.2 | Secondary sideroblastic anemia due to drugs and toxins |
| D64.3 | Other sideroblastic anemia |
| D64.4 | Congenital dyserythropoietic anemia |
| E80.1 | Porphyria cutanea tarda |
| E83.10 | Disorders of iron metabolism, unspecified |
| E83.110 | Hereditary hemochromatosis |
| E83.111 | Hemochromatosis due to repeated red blood cell transfusions |
| E83.118 | Other hemochromatosis |
| K70.0-K70.9 | Alcoholic liver disease |
| K76.0 | Fatty (change of) liver, not elsewhere classified |

| Reviews, Revisions, and Approvals | Date | Approval Date |
|---|---|---|
| Policy Developed. | 12/18 | |

**References**
1. ACR. Practice Guideline for the Performance of Magnetic Resonance Imaging (MRI) of the Liver. Amended 2015 (Res. 3). Accessed at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/MR-Liver.pdf
2. ACR-ASNR-SPR Practice parameter for the performance of functional magnetic resonance imaging (fMRI) of the brain.  Amended 2014 (Res. 39).  Accessed at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/fmr-brain.pdf?la=en
3. FerriScan® R2-MRI Fact Sheet.  Resonance Health.  Revised March 2015.  Accessed at: http://www.resonancehealth.com/images/files/FerriScan/FerriScan%20Fact%20Sheet%20Mar%202015.pdf
4. Fischer R, Harmatz PR.  Non-invasive assessment of tissue iron overload. Hematology Am Soc Hematol Educ Program. 2009:215-21
5. Schrier SL, Bacon BR.  Approach to the Patient with Suspected Iron Overload.  In: UpToDate, Mentzer WC, Mahoney DH (Ed), UpToDate, Waltham, MA, 2015. Accessed October 4, 2018                .
6. Taher A, Musallam KM, El Rassi F, et al.  Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. British Journal of Haematology, 146: 569–572. doi: 10.1111/j.1365-2141.2009.07810.x.

7. Kwiatkowski JL, Kim HY, Thompson AA, et al. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood. 2012 Mar 22; 119(12): 2746–2753. doi: 10.1182/blood-2011-04-344507

8. Wood JC, Pressel S, Rogers ZR, et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baselines results from the TWiTCH trial. Am J Hematol. 2015 Sep; 90(9): 806–810. doi: 10.1002/ajh.24089.

9. Wood JC, Zhang P, Rienhoff H, Abi-Saab W, Neufeld EJ. Liver MRI is more precise than liver biopsy for assessing total body iron balance: a comparison of MRI relaxometry with simulated liver biopsy results. Magn Reson Imaging. 2015 Jul;33(6):761-7. doi: 10.1016/j.mri.2015.02.016. Epub 2015 Feb 20.

10. Hernando D, Levin YS, Sirlin CB, Reeder SB. Quantification of liver iron with MRI: State of the art and remaining challenges. J Magn Reson Imaging. 2014 Nov; 40(5): 1003–1021.

11. Tamary H, Dgany O. Congenital Dyserythropoietic Anemia Type 1. Eds: Pagon RA, Adam MP, Wallace SE, et al. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. 2009 Apr 21 [updated 2016 Aug 25].

12. d'Assignies G, Paisant A, Bardou-Jacquet E, et al. Non-invasive measurement of liver iron concentration using 3-Tesla magnetic resonance imaging: validation against biopsy. Eur Radiol. 2018 May;28(5):2022-2030. doi: 10.1007/s00330-017-5106-3. Epub 2017 Nov 24.